WallStSmart

EchoStar Corporation (SATS)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

EchoStar Corporation generates 23% more annual revenue ($15.00B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs -96.6%. SATS appears more attractively valued with a PEG of 1.34. VRTX earns a higher WallStSmart Score of 66/100 (B-).

SATS

Avoid

34

out of 100

Grade: F

Growth: 2.0Profit: 3.0Value: 7.0Quality: 2.5
Piotroski: 3/9Altman Z: -0.08

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SATSUndervalued (+66.0%)

Margin of Safety

+66.0%

Fair Value

$323.23

Current Price

$127.15

$196.08 discount

UndervaluedFair: $323.23Overvalued
VRTXUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$992.87

Current Price

$429.82

$563.05 discount

UndervaluedFair: $992.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SATS0 strengths · Avg: 0/10

No standout strengths identified

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

SATS4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-111.3%2/10

ROE of -111.3% — below average capital efficiency

Revenue GrowthGrowth
-4.3%2/10

Revenue declined 4.3%

EPS GrowthGrowth
-85.6%2/10

Earnings declined 85.6%

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : SATS

PEG of 1.34 suggests the stock is reasonably priced for its growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : SATS

The primary concerns for SATS are Piotroski F-Score, Return on Equity, Revenue Growth. Debt-to-equity of 4.40 is elevated, increasing financial risk.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

SATS profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.

SATS carries more volatility with a beta of 0.96 — expect wider price swings.

VRTX is growing revenue faster at 7.8% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 34/100), backed by strong 35.5% margins. SATS offers better value entry with a 66.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EchoStar Corporation

COMMUNICATION SERVICES · TELECOM SERVICES · USA

EchoStar Corporation provides broadband satellite technologies and broadband Internet services. The company is headquartered in Englewood, Colorado.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?